Ji et al. [15]
|
RCT, parallel
|
24 patients
|
PD ≥4 mm, BOP + no radiographic bone loss compared with baseline (i.e. immediately after prosthesis installation)
|
3 months
|
OHI + mechanical debridement (ultrasonic scaler with carbon fibre tips) + air abrasive device, glycine powder (sites with PD ≥4 mm)
|
OHI + mechanical debridement (ultrasonic scaler with carbon fibre tips)
|
Test
|
| |
33 implants
| | | |
BI: 1.4 (0.57) (BL) to 1.1 (0.58) (3 months, subject level)
|
| |
Molar/premolar sites
| | | | |
BI: 1.7 (0.93) (BL) to 1.1 (0.98) (3 months, implant level)
|
| |
1 implant system
| | | | |
Sites without bleeding: 29.3 %
|
| | | | | | |
PD: 3.6 (0.47) (BL) to 3.2 (0.48) mm (3 months, subject level)
|
| | | | | | |
Control
|
| | | | | | |
BI: 1.5 (0.65) (BL) to 1.0 (0.85) (3 months, subject level)
|
| | | | | | |
BI: 1.7 (1.0) (BL) to 0.9 (1.1) (3 months, implant level)
|
| | | | | | |
Sites without bleeding: 42 %
|
| | | | | | |
PD: 3.5 (0.5) (BL) to 3.1 (0.38) mm (3 months, subject level)
|
De Siena et al. [18]
|
CCT, parallel
|
30 patients
|
BOP or spontaneous bleeding with local swelling
|
6 months
|
OHI + mechanical debridement Teflon curettes, polishing) + air abrasive device, glycine powder
|
OHI + mechanical debridement Teflon curettes, polishing)
|
Test
|
| |
No information on number and types of implants
|
PD ≤3.5 mm
| | | |
PD: 3.0 (0.4) (BL) to 2.4 (0.5) mm (6 months, subject level)
|
| | |
Bone loss ≤ 3.0 mm
| | | |
13 patients did not present bleeding at 6 months
|
| | | | | | |
Control
|
| | | | | | |
PD: 2.9 (0.4) (BL) to 3.0 (0.6) mm (6 months, subject level)
|
| | | | | | |
9 patients did not present bleeding at 6 months
|
| | | | | | |
BI and PD scores sign. lower in the test group at 6 months
|
Riben Grundström et al. [21]
|
RCT, parallel
|
37 patients
|
PD ≥4 mm, BOP + with or without suppuration
|
12 months
|
OHI + air abrasive device, glycine powder
|
OHI + mechanical debridement (ultrasonic scaler with plastic coated tips)
|
Test
|
| |
One implant per subject used
|
Bone loss ≤2 mm from implant shoulder
| |
Repeated treatment at 3 and 6 months
|
Repeated treatment at 3 and 6 months
|
BOP: 43.9 (7.3) (BL) to 12.1 (3.8) % (12 months, subject level)
|
| |
Test N = 19
| | | | |
Number of diseased sites (pocket depth ≥4 mm with bleeding/suppuration)
|
| |
Control N = 18
| | | | |
38 % (BL) to 8 % (12 months, subject level)
|
| | | | | | |
Control
|
| | | | | | |
BOP: 53.7 (7.9) (BL) to 18.6 (6.4) % (12 months, subject level)
|
| | | | | | |
Number of diseased sites (pocket depth ≥4 mm with bleeding/suppuration)
|
| | | | | | |
52 % (BL) to 17 % (12 months, subject level)
|
| | | | | | |
No significant differences between groups for either reduction of
|
| | | | | | |
BOP or of diseased sites
|